Navigation Links
Silence Therapeutics Announces Issuance of Japanese Patent for Screening Therapeutics Against Key Pathway Associated with Cancer and Other Diseases
Date:9/16/2011

s.

The Company's lead internal drug candidate is Atu027, a liposomal formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutic candidates in the area of oncology. Atu027 incorporates two of the Company's technologies, AtuRNAi and AtuPLEX. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as repeated, intravenous administration. Encouraging interim data were presented at the American Society of Clinical Oncology Annual Meeting in June 2011. The results of this study are expected in the first half of 2012.

The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer/Quark, and Novartis/Quark. Silence is actively pursuing the establishment of additional partnerships. Silence Therapeutics has operations in both Berlin and London.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.

For further information, please contact:

Silence Therapeutics Singer Capital Markets Max Herrmann/Thomas Christely Shaun Dobson/Claes Spång +44(0)20-7491-6520/ +49-30-9489-2800 +44(0)20-32057500 m.herrmann@silence-therapeutics.com shaun.dobson@singercm.com t.christ
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Silence Therapeutics and InteRNA Technologies Sign Collaboration to Develop Novel microRNA Therapeutics
2. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
3. Silence Therapeutics Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting
4. Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
5. Silence Therapeutics Provides Year-end Update
6. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
7. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
8. Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Silence Therapeutics Announces Board Changes
11. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015  Thoratec Corporation (NASDAQ: THOR ... save, support and restore failing hearts, announced today that ... role of President, International. This new ... operations outside of North America , including ... and Latin America , and reports directly ...
(Date:5/1/2015)...  CytRx Corporation (CYTR), a biopharmaceutical research and ... results for the three months ended March 31, ... and upcoming milestones for its clinical development programs. ... early months of 2015, including the announcement of ... in patients with soft tissue sarcoma, and positive ...
(Date:5/1/2015)... 1, 2015 The Institute for Healthcare Advancement ... award winners. The IHA Health Literacy Awards aim to ... on the practice of educating or empowering organizations to ... awards in three categories: innovative programs, published materials and ... Hero award. In the area of innovative ...
Breaking Medicine Technology:Thoratec Announces Addition To Senior Management Team 2Thoratec Announces Addition To Senior Management Team 3CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11Institute for Healthcare Advancement Announces 2015 Award Winners 2
... International Corporation (NASDAQ: PRXL ) announced today ... Conference in Boston, MA.  Josef von Rickenbach, Chairman and ... PAREXEL at 3:30 p.m. ET on Monday, March 5, 2012. ... presenting at the Raymond James Investors Conference in Orlando, ...
... ReportsnReports adds new market research report , ... and Market Forecasts to 2018 , to its ... $1,412.8m by 2018 growing at a CAGR of 5%. The ... for minimally invasive procedures and technology advances that make surgery ...
Cached Medicine Technology:PAREXEL International to Present at Cowen Healthcare Conference and Raymond James Investors Conference 2Electrosurgical Devices Market to Grow at a CAGR of 5% Globally From 2011-2018 2Electrosurgical Devices Market to Grow at a CAGR of 5% Globally From 2011-2018 3Electrosurgical Devices Market to Grow at a CAGR of 5% Globally From 2011-2018 4
(Date:5/3/2015)... Orion, Clarkston, Metamora, Michigan (PRWEB) May 03, 2015 ... She has worked to enhance the well being of the men, ... generalist in a hospital, followed by providing care for families in ... with as an Adult Nurse Practitioner began wondering if I could ... the birth of my own children with my mentor Nurse Midwife, ...
(Date:5/3/2015)... ANGELES, American Telemedicine Association 2015 Meeting & Tradeshow ... e-health solutions, a full-service telemedicine and mobile health ... new platform, VITA health services for chronic disease ... services platform enables remote patient monitoring of a ... heart failure (CHF), diabetes, COPD, hypertension and other ...
(Date:5/3/2015)... 2015 " Bubbly Walrus ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... game. , The best games to play on smartphones are ... users killing brain cells with a video game that just ...
(Date:5/3/2015)... 2015 “ BolehVPN ” was featured on ... the latest and coolest technology products available to consumers. Scott ... the review and shared with viewers how to protect their ... days is on computers and even more so online. It ... people all over the world. In terms of work, the ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 NuevaCare announced ... at two upcoming area seminars. The first event will ... Annual Regional Stroke Conference to be held at The ... on Wednesday, May 13 during the Dementia Conference to ... , “These seminars offer an excellent opportunity to learn ...
Breaking Medicine News(10 mins):Health News:Women's Excellence In Midwifery Welcomes Barbara Crone 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 3Health News:An Application to Have Fun with Mathematics Was Featured on NewsWatch Television 2Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2
... found out that a protein called NMNAT can delay the ... level. The researchers from Baylor College of// Medicine in a ... online today said that NMNAT protects against nerve cell degeneration ... the question if a drug might be developed that could ...
... wines that belong to the vineyards of France and Italy are ... effects of fatty meals on the heart can be offset by ... has shown. Wines from these regions contain high levels of a ... have also proved the heart healthy benefits of a daily glass ...
... Center and colleagues at four other medical centers have ... that may contribute to early atherosclerosis. ,“If we ... life who have a genetic predisposition to develop atherosclerosis, ... and stroke sooner and more aggressively,” said David Herrington, ...
... a new drug that might cease men from ejaculation during ... on is that the contraction of the longitudinal muscle in ... out of the penis. ,This method of contraception ... to which researchers claim have chemicals to block male sperms. ...
... unknown immunodeficiency disease was discovered by scientists about twenty-five ... 'AIDS'. //Ever since, 'Acquired Immune Deficiency Syndrome' or AIDS, ... to the latest figures enabled by the UNAIDS/WHO 2006 ... world are grappling with the disease. ,AIDS ...
... Research, the data from Population Based Cancer Registry, Delhi ... specific// incidence rates of breast cancer below 40 years ... National Cancer Control Programme (NCCP), special emphasis is now ... awareness. Grant-in-aid is provided to Non-Governmental Organisations to create ...
Cached Medicine News:Health News:NMNAT Protein Protects Against Nerve Cell Degeneration 2Health News:Study Underway to Identify Genes Contributing to Heart Attack Risk 2Health News:'Red'y to Fight HIV – 'AbstinenceBehaviorCondom', Sacrosanct to AIDS Preventio 2Health News:'Red'y to Fight HIV – 'AbstinenceBehaviorCondom', Sacrosanct to AIDS Preventio 3Health News:'Red'y to Fight HIV – 'AbstinenceBehaviorCondom', Sacrosanct to AIDS Preventio 4
... proteins produced with recombinant technology, that have been ... capable of detecting the different types of T.cruzi ... with amino acid sequences repeated in tandem. SAPA ... phase of the infection, it reacts with 93% ...
Elisa test for qualitative detection of Total antibodies to Trypanosoma Cruzi in human serum or plasma....
... defibrillator lead features a patented ... flexibility and maneuverability of a ... physician who prefers a lead ... SPL lead also promotes low ...
TVL defibrillation leads have a patented coiled-coil design for faster, easier insertion and more precise intracardiac placement. Designed with an integrated bipolar design, the lead enables high-vol...
Medicine Products: